semaglutide chronic kidney disease stage 3 dosing Semaglutides Are Poised to Remake Care Weight Loss Injections for Chronic

GLP-1 in addiction medicine: GLP-1 acts on pancreas, gut, kidney, heart and thyroid receptors to activate reward/stress hubs (VTA, NAc, ARC, PFC, hypothalamus)

CagriSema is a fixed-dose combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist), and is currently an experimental obesity drug developed by Novo Nordisk

Just a little influencer, trying to live a good life and bring joy to others | A comparison between Semiglutide and Tirzepatide, focusing on their brand names, receptors affected, administration methods, and effects on HbA1c and body weight

Bruising after tirzepatide injection is a common but manageable side effect

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D)

Ozempic's standard weekly injection schedule works for most patients, but some wonder if spacing doses 10 days apart could still deliver results